The clinical potential of Deprenyl in neurologic and psychiatric disorders.
This article reviews the results of clinical studies with Deprenyl in various neurologic and psychiatric disorders except Parkinson's disease. Promising results could be observed both in narcolepsy in a dose of at least 20 mg/day in three different trials and in one study of Tourette's syndrome including attention hyperactivity disorders using an average dosis of 8.1 mg/ day. Controversial results were reported for Alzheimer's disease. On the one hand significant improvement of cognitive functions was found by various authors. On the other hand in a more recent study no effect on the progression of the disease could be observed. For depression a higher dosage of deprenyl between 30 to 60 mg/day appears to be necessary for effective treatment. No positive results were found in amyotrophic lateral sclerosis and in tardive dyskinesias.
Kuhn
W
W
Department of Neurology, St. Josef-Hospital, Bochum, Federal Republic of Germany.
Müller
T
T
D000328:Adult; D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy; D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy; D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D018592:Cross-Over Studies; D003863:Depression / Q000188:drug therapy; D004311:Double-Blind Method; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D009290:Narcolepsy / Q000188:drug therapy; D009422:Nervous System Diseases / Q000188:drug therapy*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D018697:Nootropic Agents / Q000627:therapeutic use*; D010302:Parkinson Disease, Secondary / Q000188:drug therapy; D012559:Schizophrenia / Q000188:drug therapy; D012642:Selegiline / Q000627:therapeutic use*; D013494:Supranuclear Palsy, Progressive / Q000188:drug therapy; D005879:Tourette Syndrome / Q000188:drug therapy; D016896:Treatment Outcome
D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D008996:Monoamine Oxidase Inhibitors; D018696:Neuroprotective Agents; D018697:Nootropic Agents; D012642:Selegiline